Green Alpha Advisors, LLC Cure Vac N.V. Transaction History

Green Alpha Advisors, LLC

$112 Million
Q4 2024

A detailed history of Green Alpha Advisors, LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Green Alpha Advisors, LLC holds 26,037 shares of CVAC stock, worth $99,461. This represents 0.08% of its overall portfolio holdings.

Number of Shares

26,037

Previous 27,319 4.69%

Holding current value

$99,461

Previous $80,000 10.0%

% of portfolio

0.08%

Previous 0.06%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 13, 2025	SELL	$2.49 - $3.41 $3,192 - $4,371	-1,282 Reduced 4.69%	26,037 $88,000
Q3 2024 Oct 07, 2024	BUY	$2.74 - $3.79 $21,862 - $30,240	7,979 Added 41.26%	27,319 $80,000
Q2 2024 Aug 13, 2024	SELL	$2.31 - $4.99 $6,417 - $13,862	-2,778 Reduced 12.56%	19,340 $65,000
Q1 2024 Apr 09, 2024	BUY	$2.94 - $4.34 $2,490 - $3,675	847 Added 3.98%	22,118 $67,000
Q4 2023 Jan 04, 2024	SELL	$3.96 - $6.41 $1,928 - $3,121	-487 Reduced 2.24%	21,271 $89,000
Q3 2023 Oct 10, 2023	BUY	$6.5 - $10.77 $66,729 - $110,564	10,266 Added 89.33%	21,758 $148,000
Q2 2023 Jul 06, 2023	SELL	$6.69 - $12.25 $5,746 - $10,522	-859 Reduced 6.95%	11,492 $119,000
Q1 2023 Apr 06, 2023	SELL	$6.38 - $12.5 $835 - $1,637	-131 Reduced 1.05%	12,351 $86,000
Q4 2022 Jan 12, 2023	SELL	$5.75 - $8.5 $667 - $986	-116 Reduced 0.92%	12,482 $0
Q3 2022 Oct 14, 2022	BUY	$7.48 - $15.24 $2,625 - $5,349	351 Added 2.87%	12,598 $99,000
Q2 2022 Jul 08, 2022	BUY	$13.18 - $19.41 $161,415 - $237,714	12,247 New	12,247 $167,000
Q4 2021 Jan 12, 2022	SELL	$33.72 - $48.22 $174,332 - $249,297	-5,170 Closed	0 $0
Q3 2021 Oct 12, 2021	BUY	$49.26 - $74.5 $30,787 - $46,562	625 Added 13.75%	5,170 $282,000
Q2 2021 Jul 22, 2021	BUY	$56.91 - $127.53 $258,655 - $579,623	4,545 New	4,545 $334,000

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.2M

Call Options Held

164K

Put Options Held

117K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $716M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Green Alpha Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Green Alpha Advisors, LLC with notifications on news.

Account

Green Alpha Advisors, LLC Cure Vac N.V. Transaction History